Lake Street analyst Brooks O’Neil initiated coverage of LifeMD (LFMD) with a Buy rating and $12 price target
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFMD:
- GE Vernova initiated, Merck upgraded: Wall Street’s top analyst calls
- LifeMD initiated with a Neutral at Mizuho
- ADA advises doctors, patients not to use compounded GLP-1s
- Hims & Hers jumps as status report says patients unable to obtain branded GLP-1s
- LifeMD price target raised to $12 from $11 at B. Riley